Sativa Wellness Group Management Share Compensation Arrangements

Sativa Wellness Group plc (AQSE:SWEL / CNSX:SWEL) today announced certain management share compensation arrangements and amendments that have been approved by the Board of Directors with a view to both incentivising and aligning management and shareholder interests.

Firstly, following an administrative error, it has been necessary to cancel and reissue the options and warrants announced on 12 July 2021.  As a result, Marc Howells, Chief Executive Officer, has had options reissued in respect of 1,447,173 common shares of the Company, under an EMI Option Agreement entered into on 20 December 2021. These options vest immediately, have an exercise price of C$0.065 per Sativa Wellness common share, being the prevailing market price on issue, and are valid for 5 years.

In addition, a consultant to the Company has had warrants reissued in respect of 1,447,173 common shares of the Company, that vest immediately, have an exercise price of C$0.065 and are valid for 3 years.

Management Incentive Plan (“MIP”)

In addition, 32,222,222 G shares in the Company’s subsidiary, Goodbody Botanicals (“G Shares”), convertible into 10,796,700 common shares of the Company, have been acquired by certain directors of the Company.

The G Shares relate to the MIP, as detailed in Company’s Scheme Document dated 22 July 2020, and have been reallocated from previous G shareholders. There is no change in the total number of issued G Shares. 

Marc Howells, Chief Executive Officer, has acquired 30,000,000 G Shares, convertible into 10,052,100 common shares of the Company at C$0.00433 per Sativa Wellness common share for a remaining term of 5 years.

Further, the Company announces that Anne Tew, Chief Finance Officer, has acquired 2,222,222 G shares, convertible into 744,600 common shares of the Company at C$0.00433 per Sativa Wellness common share for a remaining term of 5 years.

The Company has a total of 36,903,461 options including G shares and 49,317,379 warrants outstanding.

Click to view all articles for the EPIC:
Or click to view the full company profile:

More articles like this

Use of Cannabidiol for the treatment of Anxiety

A macro-analysis of 49 different research papers (focusing primarily on animal studies) on the effects of CBD regarding multiple anxiety or stress-oriented disorders, such as Post-Traumatic Stress Disorder, Generalised Anxiety Disorder, and Social Anxiety Disorder to

The “Runner’s High” and Endocannabinoids

A runner’s high is a sense of well-being some people experience after prolonged exercise. For decades, it was hypothesized that exercise-induced endorphin release is solely responsible for a runner’s high, but recent evidence has suggested that

CBD bioavailability and why it matters

Wealth, friends, and even spouses, if lost, can be regained or acquired again somehow. But the body, once gone, will never come back- no matter how hard we try to revive the life that’s lost. Our

Finding relief from aches and pains

Everyone at some point of their life will experience some aches and pain, and it could be because of a whole range of different reasons. For some of us, that would be a bit of joint

CBD and mental health: A systematic analysis

There is a lot of research about the positive effects of CBD and Mental Health.  This report is a systematic analysis of a multitude of different research papers and conducted trials with regards to CBD’s impact

General benefits of CBD

CBD has been reported to help people in a number of ways. From pain relief, memory, and sleep to name a few, there’s a chance that we could all benefit from CBD in one way or

CBD and Diabetes: How can it help?

Close to 4.9 million people in the UK have been diagnosed with diabetes, with a further 850,000 people suspected to be living with undiagnosed type 2 diabetes. To add on to this, 13.6 million people in

The effects of cannabidiol on cerebral blood flow

The primary aim of this research paper was to investigate how CBD influences cerebral blood flow (CBF) in regions involved in memory processing. It was conducted under a randomised, crossover, double-blind design in which 15 healthy

Sativa Wellness Group Report record Q3 revenues (Interview)

Sativa Wellness Group Inc. (AQSE:SWEL / CNSX:SWEL) CEO Mark Howells joins DirectorsTalk Interviews to discuss a record quarterly profit in Q3 2021. Mark talks us through the numbers, explains how sustainable the performance is and plans

Cannabidiol’s use as chronic pain treatment

This paper reviews the basic research regarding the molecular mechanism of CBD’s action with particular focus on its analgesic potential for chronic pain treatment, as well as describing the detailed analgesic and anti-inflammatory effects of CBD